Roche Glycart

About:

Roche Glycart is a biotechnology company, engages in the research, development, and commercialization of antibody-based products.

Website: http://www.roche.ch/schlieren.html

Top Investors: Forbion Capital Partners, Novartis Venture Fund, Gilde Healthcare, BioMedPartners, Quest Capital Management, Inc .

Description:

Roche Glycart develops antibody drug candidates, which include GA101, a humanized anti-CD20 monoclonal antibody to increase direct- and immune-mediated target cell death; and GA201, a humanized glycoengineered antibody for solid tumors.